Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Journal
The New England journal of medicine
Journal Volume
384
Journal Issue
12
Date Issued
2021
Author(s)
Bieber, Thomas
Simpson, Eric L
Silverberg, Jonathan I
Thaçi, Diamant
Paul, Carle
Pink, Andrew E
Kataoka, Yoko
DiBonaventura, Marco
Rojo, Ricardo
Antinew, Jeremias
Ionita, Ileana
Sinclair, Rodney
Forman, Seth
Zdybski, Jacek
Biswas, Pinaki
Malhotra, Bimal
Zhang, Fan
Valdez, Hernan
Abstract
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.
SDGs
Other Subjects
abrocitinib; dupilumab; placebo; abrocitinib; dupilumab; immunoglobulin A; interleukin 4 receptor alpha; Janus kinase 1; monoclonal antibody; placebo; protein kinase inhibitor; pyrimidine derivative; sulfonamide; adult; Article; atopic dermatitis; comparative effectiveness; controlled study; dose response; double blind procedure; drug dose comparison; drug safety; female; human; loading drug dose; major clinical study; male; nausea; phase 3 clinical trial; priority journal; prospective study; randomized controlled trial; skin pruritus; atopic dermatitis; blood; clinical trial; comparative study; multicenter study; oral drug administration; pruritus; severity of illness index; subcutaneous drug administration; Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunoglobulin A; Injections, Subcutaneous; Interleukin-4 Receptor alpha Subunit; Janus Kinase 1; Male; Placebos; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Severity of Illness Index; Sulfonamides
Type
journal article